Contents
On this page
- Cost of a single application
- Base rates of success
- Absence of pharmaceutical-specific evidence
- Effect of shorter application forms on preparation burden
- Characteristics distinguishing funded from unfunded applications
- Challenges specific to pharmaceutical research
- Management of an application portfolio
- Approaches that reduce the cost of applications
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · pharmaceutical grant challenges
Challenges for Research Scholars in Writing Pharmaceutical Research Grant Proposals: Costs, Success Rates and Evidence
The principal difficulty in writing a research grant lies not in the writing itself but in the low base rate of success, a time cost measured in weeks of full-time work, and the fact that almost none of that cost is recoverable if the application fails. This article presents the measured figures and states explicitly that the evidence derives from biomedical and general science funders, because research specific to pharmaceutical grants is essentially absent.
Research scholars preparing a first pharmaceutical grant application are commonly advised that the principal challenge is one of craft: refining the aims, strengthening the statement of significance and following the guidelines. Craft is important, but the principal difficulty is quantitative. Rejection rates are 80 to 90 per cent, a competitive proposal requires six to twelve months to prepare, and the time involved has been measured at 170 to 270 hours per application. Knowledge of these figures before beginning informs the choice of proposals and the organisation of the year around them.
Learning objectives
- The cost of a single grant application in hours and in salary terms
- The reported base rates of success at major funders, and their implications for planning
- The reasons simplification of the application form did not reduce the burden, and the implications of this finding
- The characteristics that distinguish funded from unfunded applications in the one dataset that scored both
- The distinction between challenges specific to pharmaceutical research and those common to all grant applications
- The basis for a decision to proceed or not to proceed with a call before substantial time has been invested
Common misconceptions
- “Sound science is sufficient for a proposal to succeed.” With rejection rates of 80 to 90 per cent and success rates reported below 15 per cent for Horizon 2020 and below 20 per cent for the US National Institutes of Health, most rejected applications do not represent poor science. Planning on the assumption that sound science is sufficient results in a single application each year with no alternative.
- “Grant writing requires only a few periods of intensive work.” Australian researchers spent an average of 34 working days per NHMRC (National Health and Medical Research Council) proposal, and estimates of researcher time per application range from 170 to 270 hours. This represents weeks of full-time work.
- “Shorter application forms would reduce the burden.” When one funder simplified its application form, average preparation time rose from 34 to 38 working days and applications per researcher rose from 2.2 to 3.1. Reducing the cost per application increased the number of applications, and the total burden increased.
- “A resubmission is nearly as much work as a new application.” It is measurably less: 28 working days for resubmissions against 38 for new proposals in the same dataset. Resubmission is the least costly opportunity available, which supports the preparation of a reviewable first submission rather than a perfect one.
- “A substantial literature exists on pharmaceutical grant writing.” No substantial peer-reviewed literature exists. The evidence on grant burden, review reliability and proposal weaknesses derives from biomedical and general science funders. It is likely to be transferable, but readers should be aware that it is being extrapolated.
Cost of a single application
The measurement should be considered first, because it is the fact most likely to change applicant behaviour. Estimates of researcher time per proposal range from 170 to 270 hours, costing approximately 8,500 to 13,400 US dollars in salary and about 20,000 dollars once overhead is included 9,22. In a separate Australian study, researchers spent an average of 34 working days per NHMRC proposal (38 days for a new application and 28 for a resubmission), and across 3,727 proposals, 550 working years of researcher time were invested in a round in which 21 per cent were funded 28,36.
The last figure merits particular consideration. Five hundred and fifty working years is not an abstraction; it represents the collective research output forgone by a national research community in one funding round. The same cost is also evident on a weekly basis: researchers at US R1 universities spend on average more than four hours a week writing applications, within a system through which the NIH allocates over 30 billion dollars a year by project peer review 16.
None of these figures is specific to pharmaceutical research. They derive from national biomedical funders and general science programmes. There is no reason to expect the burden to be lower for a pharmaceutical sciences application, and the additional regulatory, formulation and intellectual-property material may suggest the opposite, but this cannot be demonstrated from the available evidence, and the limitation is therefore stated explicitly.
The measured cost of a research grant application
| Measure | Figure | Source setting |
|---|---|---|
| Researcher hours per proposal | 170 to 270 hours | Estimates of researcher time per application |
| Salary cost of that time | Roughly $8,500 to $13,400 | Same estimates, salary only |
| Full cost including overhead | About $20,000 per application | Same estimates, overhead included |
| Working days, new proposal | 38 days | Australian NHMRC applicants |
| Working days, resubmission | 28 days | Australian NHMRC applicants |
| Working days, average across both | 34 days | Australian NHMRC applicants |
| Aggregate researcher time, one round | 550 working years across 3,727 proposals, 21 per cent funded | Australian NHMRC round |
| Ongoing time commitment | More than 4 hours a week | Researchers at US R1 universities |
| Calendar time for a competitive proposal | 6 to 12 months | General grant literature |
All figures derive from studies of biomedical and general science funders: the Australian NHMRC, the US NIH system and general grant-burden estimates. No equivalent measurements exist for pharmaceutical sciences applications specifically; the figures are transferred, and the transfer is an assumption.
Base rates of success
Rejection rates are 80 to 90 per cent, with reported success rates below 15 per cent for Horizon 2020 and below 20 per cent for the NIH. A competitive proposal requires six to twelve months to write 9. Taken together, these figures reveal the structural problem of an early research career: at one application per year with a six-month writing period, a scholar can expect several years of unfunded effort before a successful application, and this is the typical case rather than an unfortunate one.
The implication for planning is not simply to increase effort; it is that a single application does not constitute a strategy. Three practices follow. Applicants should submit more than once per cycle where the schemes are genuinely different, because the base rate makes a single attempt likely to fail. Components should be reused deliberately: the significance argument, the team description, the facilities statement and the data-management plan remain valid across applications, and treating them as reusable assets rather than bespoke prose is the largest single saving available. Finally, the resubmission should be protected, because at 28 working days against 38 it is the most cost-effective submission in the system 28,36.
One inference requires caution. A low success rate does not mean that the process is random. It means that most fundable applications are not funded, which is a different and more discouraging fact. The Pubrica page on what scientific reviewers actually do explains how much of the variance in scores is attributable to the reviewer rather than the proposal, a proportion larger than most applicants assume 10,20.
Success rates and what they imply for planning
| Funder or scheme | Reported success rate | Planning implication |
|---|---|---|
| Across funders, general estimate | Rejection 80 to 90 per cent | A single annual application is not a strategy |
| Horizon 2020 | Below 15 per cent | Consortium building has to start before the call opens |
| US National Institutes of Health | Below 20 per cent | Resubmission should be assumed, not feared |
| Australian NHMRC, one round | 21 per cent of 3,727 proposals funded | Four in five experienced researchers went unfunded that round |
| Disease-specific research foundation | 55 of 240 applications (22.9 per cent) | Smaller funders are not easier, only smaller |
Reported success and rejection rates across Horizon 2020, the NIH, an NHMRC funding round and a disease-specific research foundation. Rates vary by scheme, career stage and year; any single figure should be treated as an order of magnitude rather than a forecast.
Absence of pharmaceutical-specific evidence
A search for research on pharmaceutical grant writing as a distinct activity yields little, and most of what exists is guidance rather than evidence. No studies were identified on what pharmaceutical sciences panels weight, no measured comparison of formulation-focused and mechanism-focused applications exists, and there are no quantitative data on how industry collaboration affects review outcomes in academic pharmaceutical funding.
This absence matters because it is easily concealed. A page purporting to teach pharmaceutical grant writing can simply apply the biomedical evidence with altered vocabulary, without informing the reader that the transfer has occurred. It is therefore stated explicitly that all quantitative content on this page derives from biomedical, clinical or general science funders. The pharmaceutical-specific sections below represent professional practice, distilled from funder guidance, call documents and reviewer practice, and should be read as reasonable defaults that may prove incorrect.
We think the transfer is safe for the burden and base-rate figures, which concern human effort and funder economics rather than any discipline’s content. We are less confident about the review-criteria evidence, because what reviewers weight plausibly does vary by field. Where that uncertainty bites, we say so in the section itself.
Effect of shorter application forms on preparation burden
The obvious policy response to the burden of grant writing is to shorten the application. One funder adopted this approach, and the result is among the most useful findings in this literature: average preparation time rose from 34 to 38 working days, and applications per researcher rose from 2.2 to 3.1 28,36. Simplifying the form did not save time. It lowered the cost of entry, which increased the number of applications, which in turn increased the total effort and exposed each application to greater competition 36.
Two implications follow for an individual applicant. First, administrative reform should not be expected to relieve the burden, because the burden is a property of the competition and not only of the paperwork 16,18. Second, and more usefully, a shorter form means that competitors also submit more applications, so the quality threshold for a short-form scheme may be higher than its page count suggests. A 1,200-word proposal is not an easier proposal; it is one in which an unresolved research question cannot be concealed.
This finding also challenges the assumption that reducing effort is always beneficial. There is a genuine tension between reducing the burden on individuals and controlling the total burden on the system, and the evidence suggests that these objectives conflict 18,21,36. It is not a solved problem, and anyone telling you otherwise is guessing.
Characteristics distinguishing funded from unfunded applications
One dataset permits examination of both sides of a funding line. Of 240 applications to a disease-specific research foundation, 55 (22.9 per cent) were funded 25. The mean review score was 3.25 for funded applications and 5.98 for unfunded ones, on a scale on which lower scores are better. More informative than the difference is its implication for sensitivity: in the same dataset, each one-point worsening of score sharply reduced the odds of funding, with an odds ratio of 0.058 per point.
This should be interpreted as a statement about margins. Funded and unfunded applications differ by approximately two and a half points of mean score, and a single point of score carries considerable weight. For this reason, apparently minor structural faults matter: a reviewer who has difficulty locating the primary objective, or who notices that the budget does not reconcile with the plan, is unlikely to reject the application outright but is likely to deduct a point, and the arithmetic determines the outcome 27,34.
In the same body of work, comments on the plan for execution appeared in 61.8 per cent of funded applications and 82.7 per cent of unfunded ones, a difference unlikely to be due to chance. Criticism of execution is almost universal, including among successful applications 25. The distinguishing feature is not its absence but the capacity of the application to withstand it, which generally requires a plan with named risks, declared contingencies and a defined unit of work rather than a statement of intent. The Pubrica page on why manuscripts are rejected covers the analogous pattern in publication.
The margin that decides funding. Mean review scores and the per-point odds ratio among 240 applications to a disease-specific research foundation, of which 55 (22.9 per cent) were funded. Lower scores are better.
Challenges specific to pharmaceutical research
In this section, the guidance is based on professional practice rather than evidence. Four problems recur in pharmaceutical sciences applications that do not arise in the same way in, for example, epidemiology proposals, and applicants should prepare for them.
Intellectual property and the publication plan pull against each other. A formulation, a delivery system or a synthetic route may be patentable, and a funder requires a dissemination plan. These requirements are reconcilable through staged disclosure and priority filing before submission of a manuscript, but the proposal must explain how, and applications that leave this implicit invite a reviewer question that cannot be answered within the resubmission window.
Industry collaboration is both an asset and a disclosure problem. Access to a compound library, a good manufacturing practice (GMP) facility or a clinical pipeline is a genuine feasibility argument and should be presented as such, with the arrangement named and the terms summarised. If left vague, it may be read as a conflict of interest that the applicant prefers not to discuss. The Pubrica page on disclosure and authorship guidance covers the declaration conventions.
Regulatory runway is usually assumed rather than argued. A proposal promising a first-in-human step within a three-year award is making a regulatory claim, and a reviewer on a pharmaceutical panel will be familiar with realistic timelines. The assumptions should be stated explicitly, and if the regulatory step lies outside the award, this should be stated.
Translational claims outrun the plan. The pressure to justify pharmaceutical work by eventual patient benefit is strong, and exaggeration tends to arise in the gap between a mechanistic aim and a clinical outcome. The benefit should be stated as the consequence of a chain of steps, with the position of the award in that chain identified. The Pubrica page on writing the rationale covers how to argue significance without overclaiming.
Declaring an industry collaboration in a pharmaceutical proposal
A vague asset that reads as a conflict
We have an established collaboration with an industrial partner who will provide access to compound libraries and formulation expertise. This partnership strengthens the translational potential of the proposed work and will facilitate rapid progression toward clinical application.
“Established collaboration” evidences nothing. No agreement, date, letter or scope is given, so the central feasibility claim of the proposal rests on an assertion that a reviewer cannot verify.
The publication position is left unstated. A reviewer who reads of an industry partnership with no publication clause is likely to assume the least favourable interpretation, based on previous experience.
No contingency. If access lapses, the proposal has no alternative, which converts a strength into a single point of failure across several aims.
No declaration of interests. Equity, consultancy and advisory relationships are what the reader is likely to question by the second sentence, and silence is the least reassuring answer.
“Rapid progression toward clinical application” is an unbacked translational claim. It names no step, no regulatory assumption and no position for this award in the chain, which is precisely the overclaim to which a pharmaceutical panel is attentive.
An evidenced arrangement with the terms declared
Access to compounds is secured under a materials transfer agreement with [Partner], executed [date] and attached as Supporting Letter 3, which provides up to [n] compounds from the [library] collection at no cost to the award and places no restriction on publication beyond a [n]-day review window for priority filing. [Partner] contributes formulation characterisation at their facility, costed as an in-kind contribution of [value] in the budget justification; no award funds transfer to [Partner]. The partnership is not a condition of any aim: Aim 2 proceeds with the smaller in-house subset if access lapses, at reduced power as set out in Risks and Alternatives. Dr [name] holds no equity in [Partner]; Dr [name] received consultancy fees in [year], declared in full at Section 12. Intellectual property arising is governed by the agreement at Supporting Letter 3, which assigns to the host institution with a non-exclusive licence option to [Partner]; our publication plan files priority before first disclosure and is unchanged by the arrangement.
The arrangement is documented, dated and attached, so the feasibility claim becomes checkable rather than rhetorical.
Publication terms and the priority-filing window are stated, which resolves the tension between intellectual property and dissemination in the text instead of leaving it to the reviewer’s inference.
A fallback is named with its cost in power acknowledged, so the partnership is an advantage rather than a dependency.
Financial interests are declared pre-emptively, which removes the question rather than inviting it.
The in-kind contribution appears in the budget justification, so the plan, the partnership and the budget reconcile — the consistency check reviewers run most reliably.
Mean review scores separated funded from unfunded applications by approximately two and a half points, and each point of worsening sharply reduced the odds of funding. An undeclared partnership may cost a point for feasibility and another for governance, and these are precisely the points that an applicant cannot afford to lose.
Management of an application portfolio
Given the base rate and the cost, the unit of planning should be the year rather than the proposal. Three practices follow directly from the measured figures.
Build a reusable asset library. Of the 170 to 270 hours per application, a large share is spent on material that is not scheme-specific: the team and track-record narrative, the facilities and equipment statement, the data-management plan, the standard methods descriptions and the significance framing for the research programme as a whole 22. These should be maintained as living documents with version dates, and only the material required by the call should be rewritten. This saving incurs no cost in quality.
Treat resubmission as a planned second attempt. At 28 working days against 38 for a new proposal, the resubmission is the most efficient submission available, and it is accompanied by a structural review at no cost in the form of the reviewers’ comments 5,28,36. Applicants who treat a rejection as a final verdict rather than one round forgo the least costly opportunity in the system. Resubmission support and response-to-reviewer work are the means by which that round is used effectively.
Decide against calls deliberately. More than four hours a week is spent on applications at research-intensive US universities, and part of that time is spent on applications with no realistic chance of success, owing to the wrong scheme, the wrong career stage or a funder priority that the work does not serve 6,7. A written decision on whether to proceed, made in one hour against the call document, is likely to be the most productive hour in grant writing. The template below supports that decision.
Approaches that reduce the cost of applications
Little in this literature supports the usual advice. Shorter forms did not help, and there is no evidence that writing faster improves outcomes. What appears to help, on the available evidence and on reasonable inference from it, is narrower in scope.
First, the proposal should be read by someone outside the project before submission, early enough for the reading to change the proposal 11,14. The evidence on the difference between funded and unfunded mean scores indicates that one or two points of score decide outcomes, and most of the available points relate to clarity and structure rather than science. Internal review must be scheduled, which in practice requires a complete draft weeks rather than days before the deadline.
Second, the execution plan should be written on the assumption that criticism of execution is certain, because it nearly is: it appeared in the majority of funded applications as well 25. This requires named risks, declared contingencies, costed tasks and a timeline that reconciles with the budget.
Third, applicants should accept the base rate and plan around it rather than against it. Applicants who expect an 80 to 90 per cent rejection rate submit differently: more applications, more reuse, more resubmissions and less catastrophising of any single outcome 9. This is not resignation; it is the only strategy that the arithmetic supports. For the mechanics of a strong first attempt, see the Pubrica guide to grant proposal writing for medical research, and the essential ingredients of a research proposal for the content checklist.
Key points
Key points
The difficulty of pharmaceutical grant writing is structural rather than literary. Rejection rates are 80 to 90 per cent, with success below 15 per cent at Horizon 2020 and below 20 per cent at the NIH; a competitive proposal requires six to twelve months and 170 to 270 hours of researcher time, at a cost of about 20,000 US dollars once overhead is included. Simplification of the form increased rather than reduced the burden: preparation rose from 34 to 38 working days and applications per researcher from 2.2 to 3.1. The margins are narrow (funded applications averaged 3.25 against 5.98 for unfunded applications, and each point of deterioration sharply reduced the odds), and criticism of execution appears in most applications, including funded ones, so the objective is to withstand such criticism rather than to avoid it. Applicants should plan on an annual basis rather than for a single application, with reusable materials, deliberate decisions on whether to proceed, and resubmission treated as the lower-cost second opportunity that the evidence shows it to be. None of these figures is specific to pharmaceutical research, because such evidence does not exist.
Application to your study
Application to your study
- Estimate the cost of the application before beginning. The applicant’s own hours should be estimated against the range of 170 to 270 hours and converted to salary costs. This estimate is the basis for a decision on whether to proceed.
- Record the decision on whether to proceed in writing. One hour should be spent assessing the call document in writing before any drafting, covering scheme fit, career-stage eligibility, funder priorities, a realistic team and the deliverable timeline. A documented decision not to proceed can save a month of work.
- Develop a library of reusable materials. The library should include the team narrative, facilities statement, data management plan, standard methods and programme-level significance, dated by version and maintained separately from any single application.
- Schedule internal review three weeks before the deadline. This should be a structural review by a person outside the project rather than a proofread, conducted early enough for the review to alter the plan.
- Write the execution plan on the assumption that it will be criticised. Comments on execution appeared in most funded applications as well as unfunded ones. The plan should include named risks, declared contingencies, costed tasks and a timeline consistent with the budget.
- Declare industry relationships and intellectual property terms explicitly. The declaration should include the agreement, date, scope, publication window, in-kind value in the budget and financial interests. Reviewers are likely to interpret omissions unfavourably.
- Plan the resubmission before the initial submission. At 28 working days against 38, resubmission offers the greatest value in the system, and the reviewers’ comments constitute a structural review at no additional cost.
Frequently asked questions
Longer than most first-time applicants expect. Australian researchers spent an average of 34 working days per NHMRC proposal: 38 days for a new application and 28 for a resubmission. Independent estimates of researcher time range from 170 to 270 hours per proposal. In calendar terms, the general grant literature estimates six to twelve months from decision to submission for a competitive application, because writing is not the longest stage: assembling preliminary data, securing collaborator commitments and reconciling the budget with the plan must all be completed first. Applicants should plan backwards from the deadline and reserve the final fortnight for reconciliation and internal review rather than for drafting the science.
Rejection rates are 80 to 90 per cent overall, with reported success below 15 per cent for Horizon 2020 and below 20 per cent for the US National Institutes of Health. One NHMRC round funded 21 per cent of 3,727 proposals. A disease-specific research foundation funded 55 of 240 applications, or 22.9 per cent. The figures vary by scheme, career stage and year, so any one of them should be treated as an order of magnitude rather than a forecast for an individual application. The useful inference concerns not the chances of a particular applicant but the fact that most fundable applications are not funded, which means that a single annual submission is a plan without a fallback.
Essentially not. No substantial peer-reviewed body of work was identified that treats pharmaceutical research grant writing as a distinct activity: there are no studies of what pharmaceutical sciences panels weight, no measured comparison of application types in that field and no quantitative data on how industry collaboration affects academic pharmaceutical funding outcomes. All measurable content on this page derives from biomedical, clinical or general science funders. The burden and base-rate figures are likely to transfer reliably, because they concern human effort and funder economics rather than disciplinary content. Confidence is lower that findings on review criteria transfer, since the weighting applied by reviewers plausibly varies by field. Any page that presents pharmaceutical grant advice as evidence-based is very probably transferring the same evidence without disclosing it.
Apparently not, and the one natural experiment available points in the opposite direction. When a funder simplified its application form, average preparation time rose from 34 to 38 working days and applications per researcher rose from 2.2 to 3.1. The mechanism is straightforward: lowering the cost of entry increased the number of applications, so total effort rose and each application faced more competition. This does not mean that form complexity is beneficial, but it does indicate that the burden is a property of the competition rather than only of the paperwork. For an individual applicant, the practical lesson is that a short-form scheme is not an easy scheme: competitors also submit more applications, and at 1,200 words an unresolved research question cannot be concealed.
In the one dataset that reports both, the effect is modest but not negligible. Among 240 applications to a disease-specific research foundation, the mean review score was 3.25 for the 55 funded applications and 5.98 for the unfunded ones, on a scale on which lower scores are better. Each one-point worsening of score sharply reduced the odds of funding, with an odds ratio of 0.058 per point. The decision margin is therefore approximately two and a half points of mean score, and a single point carries considerable weight. For this reason, apparently minor structural faults matter: a reviewer who has to search for the primary objective, or who notices that the budget does not match the plan, deducts a point rather than rejecting outright, and the arithmetic determines the outcome.
Nearly so, including for applications that are funded. In the same foundation dataset, comments on the plan for execution appeared in 61.8 per cent of funded applications and 82.7 per cent of unfunded ones, a difference unlikely to be due to chance but far from a clean separation. The practical interpretation is that criticism of execution is the normal condition of a reviewed proposal, so the objective is to withstand it rather than to avoid it. Applications that withstand it tend to have named their own risks, declared contingencies, costed the work at the level of individual tasks and produced a timeline that reconciles with the budget. Applications that do not withstand it usually described intent where a plan was expected.
Usually yes, and the economics clearly favour resubmission. Resubmissions took 28 working days against 38 for new proposals in the same dataset, and they are accompanied by a structural review in the form of the reviewers’ comments, information that could not otherwise be obtained. Given rejection rates of 80 to 90 per cent, treating a rejection as a verdict rather than one round discards the least costly opportunity in the system. The exceptions are genuine but narrow: a scheme that does not accept resubmissions, a critique that identifies a problem that cannot be resolved within the award period, or a funder priority that has moved away from the topic. In each of these cases, the appropriate course is a different scheme rather than a revised draft.
No evidence-based number exists, so the reasoning is given here instead of a figure. At 170 to 270 hours per application, a researcher spending four hours a week on applications (the average at US R1 universities) can sustain approximately one substantial new proposal plus one resubmission per year without displacing research. Increasing that number is feasible only if the marginal application is inexpensive, which in practice requires a mature library of reusable materials and a genuinely different scheme rather than a reformatted resubmission to the same panel. The pattern to avoid is volume without reuse, through which researchers contribute to the 550 working years consumed by one national round without improving their own odds.
References
- Weber-Main AM, McGee R, Steiner M, et al. A randomized trial of grant writing coaching groups: Baseline analysis of early-career scientists' research background, demographics, and mentorship variables. PLOS ONE. 2025;20(10):e0334039. doi:10.1371/journal.pone.0334039 read 9 October 2026. doi.org/10.1371/journal.pone.0334039
- Medeuov D, Rodionova K, Sabitov Z, Rodionov A. Negotiating science funding: The interplay of merit, bias, and administrative discretion in grant allocation in Kazakhstan. PLOS ONE. 2025;20(5):e0318875. doi:10.1371/journal.pone.0318875 read 9 October 2026. doi.org/10.1371/journal.pone.0318875
- Patil SG. Budgeting the Project: Detailing the Required Funding and Expenditure. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:77-91. doi:10.1007/978-981-19-7018-4_7 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_7
- Rajappa M. Checklist for Grant Proposal: Mandatory Elements. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:161-165. doi:10.1007/978-981-19-7018-4_14 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_14
- Joshi M, Joshi P, Smith JA. Dealing with the Rejected Grant Proposal: Learning from the Mistakes. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:179-187. doi:10.1007/978-981-19-7018-4_16 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_16
- Rahi M, Sharma S, Yadav B. Funders' Perspective: What the Funding Body Expects from Researchers? Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:21-31. doi:10.1007/978-981-19-7018-4_3 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_3
- Dubashi B, Ramadass B. Funding Organizations for Science and Health Care. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:33-52. doi:10.1007/978-981-19-7018-4_4 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_4
- Parija SC, Kate V (eds). Grant writing for medical and healthcare professionals. Springer, Singapore. 2023. doi:10.1007/978-981-19-7018-4 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4
- Weidmann AE, Cadogan CA, Fialova D, et al. How to write a successful grant application: guidance provided by the European Society of Clinical Pharmacy. International Journal of Clinical Pharmacy. 2023;45(3):781-786. doi:10.1007/s11096-023-01543-7 read 9 October 2026. doi.org/10.1007/s11096-023-01543-7
- Tamblyn R, Girard N, Hanley J, et al. Ranking versus rating in peer review of research grant applications. PLOS ONE. 2023;18(10):e0292306. doi:10.1371/journal.pone.0292306 read 9 October 2026. doi.org/10.1371/journal.pone.0292306
- Nachiappa Ganesh R. Tips for Improvising the Chance of Getting the Grant. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:167-177. doi:10.1007/978-981-19-7018-4_15 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_15
- Parija SC, Shrivastava SR. What Is Your Aim (Ambition-Interest-Mission), and What You Want to Do? Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:3-12. doi:10.1007/978-981-19-7018-4_1 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_1
- Kate V, Gupta D, Balakrishnan G. Writing a Grant Proposal for a Single Centre Study: Step-by-Step Approach. Grant writing for medical and healthcare professionals (Parija SC, Kate V, eds), Springer, Singapore. 2023:63-76. doi:10.1007/978-981-19-7018-4_6 read 9 October 2026. doi.org/10.1007/978-981-19-7018-4_6
- Weber-Main AM, Engler J, McGee R, et al. Variations of a group coaching intervention to support early-career biomedical researchers in Grant proposal development: a pragmatic, four-arm, group-randomized trial. BMC Medical Education. 2022;22(1):28. doi:10.1186/s12909-021-03093-w read 9 October 2026. doi.org/10.1186/s12909-021-03093-w
- Monavarian M. Basics of scientific and technical writing: Grant proposals. MRS Bulletin. 2021;46(5):455-457. doi:10.1557/s43577-021-00105-4 read 9 October 2026. doi.org/10.1557/s43577-021-00105-4
- Conix S, De Block A, Vaesen K. Grant writing and grant peer review as questionable research practices. F1000Research. 2021;10:1126. doi:10.12688/f1000research.73893.1 read 9 October 2026. doi.org/10.12688/f1000research.73893.1
- Kan P, Mokin M, Mack WJ, et al. Strategies for writing a successful National Institutes of Health grant proposal for the early-career neurointerventionalist. Journal of NeuroInterventional Surgery. 2020. doi:10.1136/neurintsurg-2020-016964 read 9 October 2026. doi.org/10.1136/neurintsurg-2020-016964
- Gross K, Bergstrom CT. Contest models highlight inherent inefficiencies of scientific funding competitions. PLOS Biology. 2019;17(1):e3000065. doi:10.1371/journal.pbio.3000065 read 9 October 2026. doi.org/10.1371/journal.pbio.3000065
- Taylor RB. How to Write a Research Protocol. Medical Writing (Springer, Cham). 2018:239-260. doi:10.1007/978-3-319-70126-4_9 read 9 October 2026. doi.org/10.1007/978-3-319-70126-4_9
- Pier EL, Brauer M, Filut A, et al. Low agreement among reviewers evaluating the same NIH grant applications. Proceedings of the National Academy of Sciences. 2018. doi:10.1073/pnas.1714379115 read 9 October 2026. doi.org/10.1073/pnas.1714379115
- Shepherd J, Frampton GK, Pickett K, et al. Peer review of health research funding proposals: A systematic map and systematic review of innovations for effectiveness and efficiency. PLoS ONE. 2018;13(5):e0196914. doi:10.1371/journal.pone.0196914 read 9 October 2026. doi.org/10.1371/journal.pone.0196914
- Boyack KW, Smith C, Klavans R. Toward predicting research proposal success. Scientometrics. 2018;114(2):449-461. doi:10.1007/s11192-017-2609-2 read 9 October 2026. doi.org/10.1007/s11192-017-2609-2
- Vaesen K, Katzav J. How much would each researcher receive if competitive government research funding were distributed equally among researchers? PLoS ONE. 2017;12(9):e0183967. doi:10.1371/journal.pone.0183967 read 9 October 2026. doi.org/10.1371/journal.pone.0183967
- Fang FC, Bowen A, Casadevall A. NIH peer review percentile scores are poorly predictive of grant productivity. eLife. 2016;5:e13323. doi:10.7554/eLife.13323 read 9 October 2026. doi.org/10.7554/eLife.13323
- Hume KM, Giladi AM, Chung KC. Factors Impacting Successfully Competing for Research Funding: An Analysis of Applications Submitted to The Plastic Surgery Foundation. Plastic and Reconstructive Surgery. 2015;135(2):429e-435e. doi:10.1097/PRS.0000000000000904 read 9 October 2026. doi.org/10.1097/PRS.0000000000000904
- Barnett AG, Herbert DL, Campbell M, et al. Streamlined research funding using short proposals and accelerated peer review: an observational study. BMC Health Services Research. 2015;15(1):55. doi:10.1186/s12913-015-0721-7 read 9 October 2026. doi.org/10.1186/s12913-015-0721-7
- Agency for Healthcare Research and Quality. Common Problems Identified During Peer Review. Agency for Healthcare Research and Quality (AHRQ). 2014. read 9 October 2026. ahrq.gov
- Herbert DL, Barnett AG, Clarke P, Graves N. On the time spent preparing grant proposals: an observational study of Australian researchers. BMJ Open. 2013;3(5):e002800. doi:10.1136/bmjopen-2013-002800 read 9 October 2026. doi.org/10.1136/bmjopen-2013-002800
- Abdoul H, Perrey C, Amiel P, et al. Peer Review of Grant Applications: Criteria Used and Qualitative Study of Reviewer Practices. PLoS ONE. 2012;7(9):e46054. doi:10.1371/journal.pone.0046054 read 9 October 2026. doi.org/10.1371/journal.pone.0046054
- National Institute of Allergy and Infectious Diseases (NIAID). Strategy for NIH Funding: Ten Steps to a Winning R01 Application. National Institutes of Health (NIAID). 2012. read 9 October 2026. ipr.osu.edu
- Proctor EK, Powell BJ, Baumann AA, et al. Writing implementation research grant proposals: ten key ingredients. Implementation Science. 2012;7(1):96. doi:10.1186/1748-5908-7-96 read 9 October 2026. doi.org/10.1186/1748-5908-7-96
- Hollins Martin CJ, Fleming V. A 15-step model for writing a research proposal. British Journal of Midwifery. 2011;18:791-798. read 9 October 2026. napier-repository.worktribe.com
- Eve J. Writing a research proposal: planning and communicating your research ideas effectively. Library and Information Research. 2009;32(102):18-28. doi:10.29173/lirg92 read 9 October 2026. doi.org/10.29173/lirg92
- SUNY Geneseo Sponsored Research (adapted from Locke, Spirduso and Silverman, Proposals That Work, 2nd ed., Sage, 1987). Common Reasons Grant Proposals Are Rejected. SUNY Geneseo Office of Sponsored Research. read 9 October 2026. geneseo.edu
- National Institute of Mental Health. Grant Writing Assistance. National Institutes of Health (NIMH). read 9 October 2026. nimh.nih.gov
- Barnett AG, Graves N, Clarke P, et al. The impact of a streamlined funding application process on application time: two cross-sectional surveys of Australian researchers. BMJ Open. 5(1):e006912. read 9 October 2026. bmjopen.bmj.com
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Challenges for Research Scholars in Writing Pharmaceutical Research Grant Proposals: Costs, Success Rates and Evidence. Pubrica. https://pubrica.com/academy/medical-writing/challenges-for-research-scholars-in-writing-pharmaceutical-research-grant/
Pubrica Academy. “Challenges for Research Scholars in Writing Pharmaceutical Research Grant Proposals: Costs, Success Rates and Evidence.” Pubrica, 9 Oct. 2026, pubrica.com/academy/medical-writing/challenges-for-research-scholars-in-writing-pharmaceutical-research-grant/.
Pubrica Academy (2026) Challenges for Research Scholars in Writing Pharmaceutical Research Grant Proposals: Costs, Success Rates and Evidence. Pubrica. Available at: https://pubrica.com/academy/medical-writing/challenges-for-research-scholars-in-writing-pharmaceutical-research-grant/ (Accessed: 15 October 2026).
Pubrica Academy. “Challenges for Research Scholars in Writing Pharmaceutical Research Grant Proposals: Costs, Success Rates and Evidence.” Pubrica. October 9, 2026. https://pubrica.com/academy/medical-writing/challenges-for-research-scholars-in-writing-pharmaceutical-research-grant/
Pubrica Academy, ‘Challenges for Research Scholars in Writing Pharmaceutical Research Grant Proposals: Costs, Success Rates and Evidence’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/medical-writing/challenges-for-research-scholars-in-writing-pharmaceutical-research-grant/> accessed 15 October 2026.
Pubrica Academy. Challenges for Research Scholars in Writing Pharmaceutical Research Grant Proposals: Costs, Success Rates and Evidence. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/medical-writing/challenges-for-research-scholars-in-writing-pharmaceutical-research-grant/
Pubrica Academy, “Challenges for Research Scholars in Writing Pharmaceutical Research Grant Proposals: Costs, Success Rates and Evidence,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/medical-writing/challenges-for-research-scholars-in-writing-pharmaceutical-research-grant/
@misc{challenges_for_research_scholars_in_wr_2026,
author = {{Pubrica Academy}},
title = {Challenges for Research Scholars in Writing Pharmaceutical Research Grant Proposals: Costs, Success Rates and Evidence},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/medical-writing/challenges-for-research-scholars-in-writing-pharmaceutical-research-grant/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Go or no-go worksheet and application cost estimate
This worksheet should be completed in one sitting, against the call document, before any drafting. Its purpose is to produce a written decision. A decision not to proceed saves four to six weeks of work, which makes this the most productive hour available in grant writing.
PART 1. GO OR NO-GO DECISION
Scheme: ______________________________
Funder: ______________________ Deadline: ______________
Call document read in full? yes / no Date read: ______________
ELIGIBILITY (any no here ends the exercise)
[ ] I meet the career-stage and position requirements
[ ] My host institution is eligible and will sign
[ ] The topic falls inside the stated scope of this call
[ ] The award duration fits the work (term allowed: ____ years)
[ ] The budget ceiling fits the work (ceiling: ______________)
[ ] I am not barred by a resubmission or concurrent-application rule
FIT (score each 1 to 5; be honest, not optimistic)
Funder priority this year matches my question ............ ____
I can name the panel's likely disciplinary composition ... ____
I have preliminary data for the central feasibility claim ____
The team covers every method in the plan ................. ____
Collaborator commitments are obtainable before deadline .. ____
I can state ONE primary objective in one sentence ........ ____
TOTAL (out of 30) ........................................ ____
WHAT I WOULD HAVE TO CREATE FROM SCRATCH
Missing preliminary data: ______________________
Can it be generated before the deadline? yes / no
Missing letters or agreements: ______________________
Lead time needed: ______ weeks Weeks available: ______
Missing regulatory or governance approval: ______________
DECISION
[ ] GO [ ] NO - wrong scheme [ ] NO - not this cycle
[ ] GO, reduced scope: ______________________
One-line reason, for my own records next year:
____________________________________________
PART 2. COST ESTIMATE (so the decision is priced)
Estimated hours, this application .................. ______
(benchmark: 170 to 270 hours per proposal;
34 working days average, 38 new / 28 resubmission)
My hourly salary cost .............................. ______
Salary cost of this application .................... ______
(benchmark: roughly $8,500 to $13,400 salary,
about $20,000 including overhead)
Expected success rate for this scheme .............. ______ %
(benchmarks: under 15% Horizon 2020; under 20% NIH;
21% one NHMRC round; 22.9% one disease foundation)
Cost per expected award = cost / success rate ...... ______
[ ] I have seen this number and still want to proceed
PART 3. REUSE AUDIT (fill before drafting anything new)
Asset Exists? Last updated Needs rewrite?
Team and track record narrative __ __________ __
Facilities and equipment __ __________ __
Data management plan __ __________ __
Standard methods descriptions __ __________ __
Programme-level significance __ __________ __
Lay or plain-language summary __ __________ __
Risk register __ __________ __
Equality or inclusion statement __ __________ __
Hours saved by reuse, estimated ................... ______
New writing genuinely required .................... ______ hours
PART 4. CALENDAR (count backwards from the deadline)
Deadline ......................................... week 0
Institutional submission cutoff .................. week -__
Final budget sign-off ............................ week -__
Internal structural review returned .............. week -__
COMPLETE DRAFT TO REVIEWERS ...................... week -3
Collaborator letters in hand ..................... week -__
Preliminary data complete ........................ week -__
Aims page fixed and circulated ................... week -__
Go or no-go decision (this worksheet) ............ week -__
[ ] The complete draft date is at least three weeks out
[ ] Nothing on the critical path depends on someone
who has not yet agreed in writing
PART 5. RESUBMISSION PLAN (write this BEFORE submitting)
If rejected, do I resubmit to this scheme? yes / no / depends on:
____________________________________________
Next deadline for this scheme: ______________
Alternative scheme if the critique is fundamental: ______________
Who reads the critique with me, and when: ______________
[ ] I have diarised the next deadline already Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica supports the components of a grant application in which the measured margins lie: the aims page, the execution plan, the risk and contingency section, and the reconciliation of the plan, the timeline and the budget justification. Pubrica also conducts routine checks of eligibility against the call document, consistency of numbering across documents and declaration of industry and intellectual property arrangements, and indicates where its advice reflects funder convention rather than evidence, as is frequently the case in pharmaceutical sciences.